newsfilter
← Latest News
Business Wire·

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be